Brain-computer interfaces (BCIs) represent a paradigmatic shift in human-system interaction, creating a technological integration with the human brain that presents unique challenges for characterizing human agency. As these invasive devices, such as deep brain stimulators, move from therapeutic clinical tools to complex, semi-autonomous systems, the traditional understanding of autonomy must be expanded. Researchers argue that current ethical frameworks remain inchoate because they fail to properly classify the different dimensions of autonomy—operational, strategic, and moral—that are involved when a technical artifact is enmeshed with the biological neural structures of a patient. Without such a conceptual framework, it becomes empirically difficult to determine how these technologies influence personal responsibility, identity, and the ability of a user to remain the authentic originator of their actions. The primary finding of recent conceptual modeling is that autonomy is not a singular property of a human agent, but a tiered capacity that can be partially delegated to a machine without compromising the user’s ultimate moral standing, provided the delegation is transparent and under the user’s broader control.
The integration of neurotechnology into the lifeworld often occurs in ways that blur the clear distinction between the human agent and the technological system. In many cases, BCIs function as “ready-to-hand” artifacts that, once surgically implemented, become part of the human, posing theoretical concerns regarding the irreversibility of potential neurobiological changes. Unlike environmental sensors, which can be identified and avoided, invasive brain-computer interfaces present a depth of engagement that cannot be easily disentangled. This is particularly problematic for clinical applications where clear authorship of decisions is required. The challenge is that BCIs, such as adaptive deep brain stimulation used to treat Parkinson’s disease or major depressive disorders, may possess a degree of autonomy in how they react to neural signals. Consequently, any framework evaluating the ethical impact of these devices must first distinguish between behavior that is merely elicited by the device’s dispositional properties and human actions that are based on normative attitudes and deontic structures.
To operationalize these concerns, the research proposes a tripartite model that classifies autonomy into operational, strategic, and moral levels. Operational autonomy concerns the technical functioning of the system, such as a device selecting specific words to translate thought into speech or controlling a robotic limb. Strategic autonomy involves the ability to select ends or prioritize goals, such as deciding when a medical intervention or lifestyle change is appropriate based on the current context. Moral autonomy represents a qualitatively different status, defined by a normative and deontic vocabulary that includes commitments, entitlements, and the capacity for moral responsibility. Technological systems may function reliably at the operational and strategic levels because their behavior is based on dispositions within the scope of alethic modality—meaning they operate according to causal chains and counterfactual robustness. However, human agency is grounded in normative statuses that cannot be reduced to these simple mechanical or computational dispositions.
The distinction between alethic and normative vocabularies is central to evaluating the ethical impact of hybrid agency. Intelligent technological systems are designed to reliably reproduce effects, such as optimizing a brain signal to alleviate a tremor or rigidity. While this operational success is beneficial, the ethical difficulty arises when the system begins to influence the patient’s lifeworld in ways that were not explicitly intended. For example, in the case of adaptive deep brain stimulation for depression, a device might automatically adjust stimulation to regulate mood. However, if the device cannot distinguish between clinical depression and the normal, context-appropriate sadness one might feel at a funeral, it risks overriding the user’s moral autonomy. Because the device lacks context-sensitive information about the human lifeworld, it can inadvertently enforce a state of well-being that is disconnected from the user’s actual emotional reality, potentially leading to a sense of alienation or the loss of an authentic self.
In the case of amyotrophic lateral sclerosis (ALS), the integration of BCIs can strengthen personal autonomy by enabling patients to regain control of communication. Here, machine learning algorithms help select letters to translate thought into speech. This is an example of a system functioning at an operational level of autonomy to provide assistance, which generally increases the patient’s personal freedom without encroaching on their moral authorship. However, even these assistive systems raise privacy concerns. The potential for the system to detect or output sensitive private thoughts, coupled with the opaque functioning of many data-collecting algorithms, requires robust security measures and transparency. Patients must understand who has access to their data and to what extent they can withhold certain internal states, as collecting data to regain functional autonomy could, if managed incorrectly, be perceived as an intrusive violation of the patient’s inner life and identity.
Epileptic seizure prediction provides a more complex case of shared autonomy, where the BCI operates autonomously to predict and potentially preempt a seizure. In such scenarios, the system is designed to intervene without the patient necessarily consenting to each occurrence of the therapeutic activation. While this may increase the user’s control and safety, it also places a greater responsibility on the user to understand the system’s states and to manage their activities accordingly. A fundamental ethical tension persists in determining criteria for when a device should override a human individual and when the human should be able to override the device. The challenge for developers is to design systems that allow the patient to maintain strategic autonomy, such as choosing when to cease a high-risk activity, without compromising the reliability of the device’s protective function.
Perhaps the most challenging cases involve personality changes induced by deep brain stimulation, as seen in reported clinical studies where patients experienced permanent manic states or radical shifts in behavior. These changes raise profound questions regarding the patient’s capacity for informed consent and their authenticity. When a device changes a patient’s personality, it becomes difficult to determine whether subsequent decisions made by that person reflect their original intentions or if they are the product of the stimulation itself. Philosophical interpretations of such cases often diverge between focusing on authenticity and focusing on autonomous competence, demonstrating that speculative reasoning without patient testimonials is insufficient. Such cases underscore the need for empirical research, using qualitative indicators to better map the intricate interplay between the user’s experience of agency and the device’s impact on their identity.
To address these complexities, the research suggests that governance must adopt a bottom-up model, incorporating the perspectives of all stakeholders, particularly the severely neurologically impaired patients and their families. Top-down, expert-driven regulation may overlook the nuanced needs of these populations. Establishing institutional frameworks, similar to the IEEE Brain initiative, could help evaluate BCIs across diverse fields by tying ethical claims to observable criteria. The use of tools like the Qualitative Agentive Competency Tool (Q-ACT) offers a path toward translating abstract ethical dimensions like responsibility, privacy, and trust into testable indicators. By establishing a framework that treats operational and strategic autonomy as delegated capabilities that remain subject to the user’s override, researchers can identify implementations that are ethically acceptable while ensuring that the core of moral authorship remains with the human agent.
The ultimate conclusion is that delegating lower levels of autonomy to technological systems is ethically permissible only if the patient’s overall autonomy is preserved or increased. This principle requires that design strategies be transparent and that the patient remains in the loop, capable of comprehending, assessing, or interrupting the system’s functioning at the strategic level. Because BCIs create a unique hybrid agency, where behavior is a product of both human intention and machine disposition, traditional concepts of liability and accountability must be updated. Designers must anticipate potential conflicts between the device’s operational logic and the complexity of the human lifeworld. Ultimately, autonomy must remain the guiding principle for governance, ensuring that while the technological system functions to alleviate symptoms or restore function, it does not dissolve the normative status of the person who uses it.
Subject of Research: Philosophy of technology and neuroethics regarding brain-computer interfaces.
Article Title: The foundational role of autonomy for brain-computer interfaces
Article References: Richter, F. (2026). The foundational role of autonomy for brain-computer interfaces. Philosophy, Ethics, and Humanities in Medicine, 21(1), Article 24. https://doi.org/10.1186/s13010-026-00231-4
Image Credits: AI Generated
DOI: 10.1186/s13010-026-00231-4
Keywords: BCI, neuroethics, autonomy, human agency, deep brain stimulation, hybrid agency, medical ethics, technological intervention, operational autonomy, strategic autonomy, moral autonomy, clinical research, machine learning, patient consent, neurotechnology, epilepsy treatment, ALS support, personality change
News Source: Cassandra Pierce. (November 18, 2026). Defining Multi-Level Autonomy Models for Brain-Computer Interfaces. Scienmag.



